Skip to main content

Advertisement

Log in

Clinical study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for glomerular proteinuria patients: A randomized controlled trial

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To explore the therapeutic effect of Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方, YQSR) in patients with glomerular proteinuria

Methods

A total of 145 patients with glomerular proteinuria were selected and randomly assigned to the treatment group (108 cases) and the control group (37 cases) according to a random number table in a ratio of 3:1. All patients received conventional and symptomatic treatment. In addition, patients in the treatment and control groups were given YQSR (200 mL, twice per day, orally) and losartan (50 mg/d orally), respectively for 6 months. The 24-h urine protein quantity, blood urea nitrogen, and serum creatinine in the two groups were measured at multiple time points before and after treatment.

Results

At the end of the study, 5 cases were lost to follow-up in the treatment group and 1 in the control group. Finally, the statistical data included 103 cases in the treatment group and 36 cases in the control group. The total effectiveness after 2, 4, and 6 months was 81.6% (84/103), 87.4% (90/103), and 92.2% (95/103), respectively, in the treatment group and 47.2% (17/36), 55.6% (20/36), and 61.1% (22/36), respectively, in the control group, with significant difference between the two groups (P<0.01 at all observation points). In the treatment group, the curative effect after 6 months was better than that after 2 months (P<0.05). The 24-h urine protein quantity was significantly lower in the treatment group at 3, 4, 5, and 6 months than that in the control group (P<0.05 or P<0.01, respectively)

Conclusion

YQSR could significantly reduce the amount of glomerular proteinuria in the early stage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a crosssectional survey. Lancet 2012;379:815–822.

    Article  PubMed  Google Scholar 

  2. Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012;8:301–306.

    Article  CAS  PubMed  Google Scholar 

  3. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003;63:809–825.

    Article  PubMed  Google Scholar 

  4. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005;12:353–365.

    Article  PubMed  Google Scholar 

  5. Erkan E, Devarajan P, Schwartz GJ. Mitochondria are the major targets in albumin-induced apoptosis in proximal tubule cells. J Am Soc Nephrol 2007;18:1199–1208.

    Article  CAS  PubMed  Google Scholar 

  6. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754–762.

    CAS  PubMed  Google Scholar 

  7. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–1863.

    Google Scholar 

  8. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511–516.

    Article  CAS  PubMed  Google Scholar 

  9. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2–15.

    Article  CAS  PubMed  Google Scholar 

  10. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012;2:139–274.

    Article  Google Scholar 

  11. Fernandez-Juarez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luno J. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 2006;17:S250–S254.

    Article  CAS  PubMed  Google Scholar 

  12. Lu WN, Zheng FP, Lai DW, Li H. Xuezhikang (血脂康) reduced renal cell apoptosis in streptozocin-induced diabetic rats through regulation of Bcl-2 family. Chin J Integr Med 2016;22:611–618.

    Article  CAS  PubMed  Google Scholar 

  13. Lee YJ, Cho S, Kim SR, Jang HR, Lee JE, Huh W, et al. Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease. Postgrad Med J 2011;87:664–669.

    Article  CAS  PubMed  Google Scholar 

  14. Praga M, Andrade CF, Luno J, Arias M, Poveda R, Mora J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003;18:1806–1813.

    Article  CAS  PubMed  Google Scholar 

  15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–S266.

  16. Zheng XY, ed. Guiding principle of clinical research of traditional Chinese medicine (Trial). Beijing: China Medical Science and Technology Press;2002:156–162.

    Google Scholar 

  17. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int 2010;77:571–580.

    Article  CAS  PubMed  Google Scholar 

  18. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998;338:1202–1211.

    Article  CAS  PubMed  Google Scholar 

  19. Floege J, Amann K. Primary glomerulonephritides. Lancet 2016;387:2036–2048.

    Article  PubMed  Google Scholar 

  20. Barbour SJ, Cattran DC, Espino-Hernandez G, Hladunewich MA, Reich HN. Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int 2015;88:1392–1401.

    Article  CAS  PubMed  Google Scholar 

  21. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217–3232.

    Article  CAS  PubMed  Google Scholar 

  22. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213–1224.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007;9:403–48.

    Article  CAS  PubMed  Google Scholar 

  24. Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother 2005;6:1539–1549.

    Article  CAS  PubMed  Google Scholar 

  25. Tian D, ed. Practical dictionary of traditional Chinese medicin. 1st ed. Beijing: People's Medical Publishing House;2002:149–153, 188–192, 530–536, 800–804, 1565–1570, 1702–1714, 1856–1862, 2219–2221.

    Google Scholar 

Download references

Acknowledgements

The authors thank all patients services staff involved in the study for recruiting, screening the eligible patients, and the clinicians for their cooperation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Li-qun He.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dai, Q., Zhang, Pq., Wang, Xq. et al. Clinical study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for glomerular proteinuria patients: A randomized controlled trial. Chin. J. Integr. Med. 24, 10–15 (2018). https://doi.org/10.1007/s11655-017-2908-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-017-2908-8

Keywords

Navigation